Cargando…

Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma

B-cell maturation antigen (BCMA) is a promising therapeutic target for multiple myeloma (MM). The aim of this study was to assess the effectiveness and tolerability of monotherapy with the conjugated anti-BCMA monoclonal antibody belantamab mafodotin in triple-class refractory patients with MM in re...

Descripción completa

Detalles Bibliográficos
Autores principales: Ntanasis-Stathopoulos, Ioannis, Malandrakis, Panagiotis, Fotiou, Despina, Migkou, Magdalini, Theodorakakou, Foteini, Roussou, Maria, Eleutherakis-Papaiakovou, Evangelos, Spiliopoulou, Vassiliki, Kastritis, Efstathios, Terpos, Evangelos, Dimopoulos, Meletios-Athanasios, Gavriatopoulou, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380484/
https://www.ncbi.nlm.nih.gov/pubmed/37511588
http://dx.doi.org/10.3390/ijms241411829
_version_ 1785080206610923520
author Ntanasis-Stathopoulos, Ioannis
Malandrakis, Panagiotis
Fotiou, Despina
Migkou, Magdalini
Theodorakakou, Foteini
Roussou, Maria
Eleutherakis-Papaiakovou, Evangelos
Spiliopoulou, Vassiliki
Kastritis, Efstathios
Terpos, Evangelos
Dimopoulos, Meletios-Athanasios
Gavriatopoulou, Maria
author_facet Ntanasis-Stathopoulos, Ioannis
Malandrakis, Panagiotis
Fotiou, Despina
Migkou, Magdalini
Theodorakakou, Foteini
Roussou, Maria
Eleutherakis-Papaiakovou, Evangelos
Spiliopoulou, Vassiliki
Kastritis, Efstathios
Terpos, Evangelos
Dimopoulos, Meletios-Athanasios
Gavriatopoulou, Maria
author_sort Ntanasis-Stathopoulos, Ioannis
collection PubMed
description B-cell maturation antigen (BCMA) is a promising therapeutic target for multiple myeloma (MM). The aim of this study was to assess the effectiveness and tolerability of monotherapy with the conjugated anti-BCMA monoclonal antibody belantamab mafodotin in triple-class refractory patients with MM in real-world practice. Patients refractory to at least one proteasome inhibitor, one immunomodulatory drug, and one anti-CD38 monoclonal antibody received belantamab mafodotin at 2.5 mg/kg intravenously every 3 weeks. Overall, 27 patients with a median age of 65 years (range 41–81) were included. Of these, 52% were male and the median number of prior lines of treatment was 5 (4–10). The overall response rate (partial response or better) was 52%, whereas the disease control rate (stable disease or better) was 70%. The median progression-free survival (PFS) was 2 months (95%CI: 0–7), whereas the median PFS among the responders was 12 months (95%CI: 6–18). Regarding the toxicity profile, the most common toxicity was eye toxicity, in 44% of the patients. Keratopathy grade 2–3 was reported in 33.3% of the patients. In conclusion, belantamab mafodotin showed a safety and efficacy profile consistent with the results of the registrational study. Importantly, heavily pretreated patients who responded to treatment derived a substantial survival benefit.
format Online
Article
Text
id pubmed-10380484
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103804842023-07-29 Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma Ntanasis-Stathopoulos, Ioannis Malandrakis, Panagiotis Fotiou, Despina Migkou, Magdalini Theodorakakou, Foteini Roussou, Maria Eleutherakis-Papaiakovou, Evangelos Spiliopoulou, Vassiliki Kastritis, Efstathios Terpos, Evangelos Dimopoulos, Meletios-Athanasios Gavriatopoulou, Maria Int J Mol Sci Article B-cell maturation antigen (BCMA) is a promising therapeutic target for multiple myeloma (MM). The aim of this study was to assess the effectiveness and tolerability of monotherapy with the conjugated anti-BCMA monoclonal antibody belantamab mafodotin in triple-class refractory patients with MM in real-world practice. Patients refractory to at least one proteasome inhibitor, one immunomodulatory drug, and one anti-CD38 monoclonal antibody received belantamab mafodotin at 2.5 mg/kg intravenously every 3 weeks. Overall, 27 patients with a median age of 65 years (range 41–81) were included. Of these, 52% were male and the median number of prior lines of treatment was 5 (4–10). The overall response rate (partial response or better) was 52%, whereas the disease control rate (stable disease or better) was 70%. The median progression-free survival (PFS) was 2 months (95%CI: 0–7), whereas the median PFS among the responders was 12 months (95%CI: 6–18). Regarding the toxicity profile, the most common toxicity was eye toxicity, in 44% of the patients. Keratopathy grade 2–3 was reported in 33.3% of the patients. In conclusion, belantamab mafodotin showed a safety and efficacy profile consistent with the results of the registrational study. Importantly, heavily pretreated patients who responded to treatment derived a substantial survival benefit. MDPI 2023-07-23 /pmc/articles/PMC10380484/ /pubmed/37511588 http://dx.doi.org/10.3390/ijms241411829 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ntanasis-Stathopoulos, Ioannis
Malandrakis, Panagiotis
Fotiou, Despina
Migkou, Magdalini
Theodorakakou, Foteini
Roussou, Maria
Eleutherakis-Papaiakovou, Evangelos
Spiliopoulou, Vassiliki
Kastritis, Efstathios
Terpos, Evangelos
Dimopoulos, Meletios-Athanasios
Gavriatopoulou, Maria
Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma
title Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma
title_full Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma
title_fullStr Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma
title_full_unstemmed Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma
title_short Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma
title_sort real-world effectiveness and safety of belantamab mafodotin monotherapy in triple-class refractory multiple myeloma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380484/
https://www.ncbi.nlm.nih.gov/pubmed/37511588
http://dx.doi.org/10.3390/ijms241411829
work_keys_str_mv AT ntanasisstathopoulosioannis realworldeffectivenessandsafetyofbelantamabmafodotinmonotherapyintripleclassrefractorymultiplemyeloma
AT malandrakispanagiotis realworldeffectivenessandsafetyofbelantamabmafodotinmonotherapyintripleclassrefractorymultiplemyeloma
AT fotioudespina realworldeffectivenessandsafetyofbelantamabmafodotinmonotherapyintripleclassrefractorymultiplemyeloma
AT migkoumagdalini realworldeffectivenessandsafetyofbelantamabmafodotinmonotherapyintripleclassrefractorymultiplemyeloma
AT theodorakakoufoteini realworldeffectivenessandsafetyofbelantamabmafodotinmonotherapyintripleclassrefractorymultiplemyeloma
AT roussoumaria realworldeffectivenessandsafetyofbelantamabmafodotinmonotherapyintripleclassrefractorymultiplemyeloma
AT eleutherakispapaiakovouevangelos realworldeffectivenessandsafetyofbelantamabmafodotinmonotherapyintripleclassrefractorymultiplemyeloma
AT spiliopoulouvassiliki realworldeffectivenessandsafetyofbelantamabmafodotinmonotherapyintripleclassrefractorymultiplemyeloma
AT kastritisefstathios realworldeffectivenessandsafetyofbelantamabmafodotinmonotherapyintripleclassrefractorymultiplemyeloma
AT terposevangelos realworldeffectivenessandsafetyofbelantamabmafodotinmonotherapyintripleclassrefractorymultiplemyeloma
AT dimopoulosmeletiosathanasios realworldeffectivenessandsafetyofbelantamabmafodotinmonotherapyintripleclassrefractorymultiplemyeloma
AT gavriatopouloumaria realworldeffectivenessandsafetyofbelantamabmafodotinmonotherapyintripleclassrefractorymultiplemyeloma